with at least 1 CV co-existing condition or 60 years and older having risk factors for CVD. It was observed that liraglutide reduces the risk for CV events, nephropathy events and all-cause mortality, when compared to placebo. Moreover, the effect of liraglutide on the CV outcomes was driven by changes in the incidence of CV death. It was inferred that the beneficial effect of liraglutide on CV effects and death appears to be independent of the lower incidence of severe hypoglycemia, baseline antidiabetic and CV medication use.